摘要
本文报告30例脑胶质瘤病人淋巴因子激活的杀伤细胞(LAK)抗肿瘤活性。杀伤 K562细胞为46.0%±17.0%,Daudi 细胞为42.2%±14.2%,自体胶质瘤细胞为40.9%±15.9%,异体胶质瘤细胞为38.7±10.8%,不杀伤自体淋巴细胞。与健康对照组相比,病人 LAK 细胞具有同等的抗肿瘤活性(p>0.05);病人 NK 活性低于对照组(P<0.05)。
Lymphokine-activated killer(LAK)cellswere induced from lymphocytes of 30 patientswith brain gliomas byusing recombinant interleukin2(IL-2),and their killing activity was examined.Their LAK cells killing activity against K562cells was 46.0±17.0% and 42.2±14.2% againstDaudi cells,40.9±15.9% against freshautologous glioma cells and 38.7±10.8% againstcultured allogeneic glioma cells.The LAK cellsdidn't kill autologous lymphocytes.Comparedwith the controlled group,the LAK cells ofpatients with gliomas were of equal killingactivity against target cells(P 0.05),whereaskilling activity of lymphocytes of patientswith glioma cultured without IL-2 against thetarget cells was lower than that of their LAKcells(P 0.01)and there was a great significantdifference.The natural killer activity of patientswith glioma was lower than that of the controlledgroup(P(?) 0.05)and there was a great significantdifference,too.This results suggested thattransfusion of autologous LAK cells into tumor-cavity(tumorbed)to treat brain gliomas isfeasible.
出处
《中华神经外科杂志》
CSCD
北大核心
1991年第3期198-200,共3页
Chinese Journal of Neurosurgery
